DB16441InvestigationalVaccines
The QazCovid-in vaccine, an inactivated vaccine, was developed and tested in the Kazakh Research Institute for Biological Safety Problems . It demonstrated high efficacy, safety, and immunogenicity at 96% in... It demonstrated high efficacy, safety, and immunogenicity at 96% in initial Phase I and II trials (NCT04530357), and will now be undergoing upcoming Phase III trials.
- Code names
- QazCovid-in
What you can answer from here — as of January 18, 2021
Which companies are running trials of QazCovid-in, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account